No cannabis-derived product has ever been approved through the FDA’s botanical drug pathway, despite four other plant-based medicines clearing this same regulatory route. A 2026 commentary from cannabis drug developers explains the scientific, regulatory, and logistical barriers responsible for this gap, while highlighting the near-total absence of preclinical data for minor cannabinoids.

Millions of patients currently use cannabis products obtained through state-regulated dispensaries, often alongside prescription medications whose interactions with cannabinoids remain poorly defined. The distance between what patients can access and what has been rigorously evaluated for safety and efficacy represents one of the most consequential gaps in modern therapeutics. Understanding why this gap persists, what structural barriers prevent its closure, and what it would take to generate FDA-grade evidence for cannabis-derived medicines is essential for clinicians who counsel patients, for researchers designing studies, and for policymakers considering scheduling reform.

The FDA’s botanical drug guidance, first issued in 2004 and revised in 2016, provides a regulatory pathway for complex plant-derived mixtures to achieve drug approval. Under this framework, the entire botanical preparation is treated as a single active entity rather than requiring isolation of individual molecules. Four non-cannabis botanicals have been approved through this pathway (Veregen, Mytesi, NexoBrid, and Filsuvez), and five cannabinoid-based drugs have received approval globally, including Epidiolex for certain pediatric epilepsies. However, the intersection of these two categories remains empty: no cannabis-derived botanical drug has ever cleared FDA approval. This commentary, authored by scientists and executives at BRC Therapeutics, a commercial cannabis drug development company, sets out to explain why.

The authors identify three primary barriers. First, the DEA’s Schedule I classification of cannabis imposes production quotas, strict security requirements, and supply-chain constraints that have no direct parallel in other pharmaceutical development programs. Second, minor cannabinoids, the plant constituents present in low concentrations alongside THC and CBD, lack even basic pharmacokinetic, pharmacodynamic, and toxicological characterization, leaving a gap too large to support Investigational New Drug applications. Third, the authors argue that most published cannabis research does not meet the design standards or regulatory relevance required for FDA submissions. They also flag cytochrome P450-mediated drug interactions as an undercharacterized safety concern. The commentary calls for multi-stakeholder collaboration among drug developers, regulators, academics, and patient advocates. It is important to note that the authors have a structural conflict of interest as employees of a company commercially pursuing the pathway they advocate, and the document presents no original data.

Zero Approvals, Enormous Potential: Why No Cannabis Product Has Cleared the FDA’s Botanical Drug Pathway

Five cannabinoid-based drugs are approved somewhere in the world. Four plant-derived botanical drugs have cleared FDA scrutiny. Yet the intersection of those two categories, a cannabis botanical drug with FDA approval, remains empty. This commentary from inside a cannabis drug development company asks why, and the answer turns out to involve federal drug scheduling, preclinical data deserts, and a widespread misunderstanding of what “botanical drug” actually means in regulatory science. What the paper gets right is important and often overlooked in public conversation: it correctly identifies the vast evidentiary chasm between a product sitting on a state dispensary shelf and one that has survived the rigor of an FDA approval process. It accurately flags minor cannabinoids as a near-total scientific blank, a domain where we lack the most basic pharmacokinetic data required even to begin formal clinical testing. These are truths that the broader cannabis enthusiasm often obscures. The analogy I find helpful here is that the FDA’s botanical drug pathway treats a whole-plant cannabis preparation the way you might evaluate a symphony orchestra as a single performer. The whole is assessed, but understanding which instruments are contributing what, and whether any are producing discord, remains an entirely separate scientific undertaking that has barely begun for cannabis.

Where I grow more cautious is where the authors’ commercial interests and their regulatory analysis begin to overlap. This is a document written by people who are building a company around the FDA botanical pathway. Their account of the challenges is detailed and largely accurate, but they do not seriously engage with the most uncomfortable questions their own framework raises. Who benefits if cannabis medicines are exclusively available through expensive FDA-approved formulations? What happens to the patients who cannot wait a decade or more for an approval that may never come? What about the large and growing body of observational evidence from state programs, which the authors dismiss as insufficiently rigorous without meaningfully evaluating? And perhaps most striking, they do not address the “entourage effect” hypothesis, the very scientific rationale most often cited for pursuing a whole-plant botanical approach over a purified isolate like Epidiolex. That silence is conspicuous. Imagine being told you must prove a new food is safe and nutritious, but that you are legally limited in how much of the ingredient you can grow, store, or ship for testing. The DEA’s scheduling creates exactly this kind of structural paradox, and the authors describe it well. But they treat it as a constraint to be managed rather than a policy failure to be reformed.

This commentary does not resolve whether any specific cannabis product works for any specific condition. That evidence remains largely unmade. What it does establish, credibly if not without bias, is that the absence of FDA-approved cannabis botanical drugs reflects genuine scientific and regulatory barriers rather than lack of interest or therapeutic implausibility. For clinicians, the takeaway is practical: understanding the evidentiary tier of any cannabis product a patient uses, whether dispensary-grade, IND-studied, or NDA-approved, is no longer optional background knowledge. It is the foundation of informed cannabis medicine. The road from plant to pharmacy is long, expensive, and structurally complicated by the same federal apparatus that was meant to protect patients. Knowing that road exists, and what it requires, is the first step toward navigating it wisely. In cannabis medicine, the absence of FDA approval does not mean a product is ineffective, and its presence on a dispensary shelf does not mean it is safe or well-characterized. The evidentiary hierarchy matters, and understanding where any given product sits within it is a core clinical literacy skill.

This commentary occupies a specific and useful niche in the cannabis evidence landscape. It does not advance clinical knowledge about any particular cannabinoid’s efficacy or safety, but it provides a rare insider map of the regulatory terrain that separates the cannabis products patients already use from the evidence-based medicines clinicians would prefer to recommend. For researchers, the document’s summary of botanical drug development stages offers a concrete framework for designing studies that could actually inform a regulatory submission, rather than adding to the growing pile of cannabis literature that lacks regulatory utility. The identification of minor cannabinoids as a critical data gap is consistent with the broader pharmacological literature and deserves attention from funding agencies.

From a pharmacological standpoint, the commentary’s emphasis on cytochrome P450-mediated drug interactions is clinically actionable even in the absence of original data. Cannabinoids, particularly CBD, are known inhibitors of CYP3A4 and CYP2C19, among other isoforms, and patients combining cannabis products with substrates of these enzymes (including many anticonvulsants, anticoagulants, and psychiatric medications) face interaction risks that are poorly quantified for whole-plant preparations. Clinicians managing patients who use cannabis alongside prescription medications should systematically screen for potential CYP450-mediated interactions, document cannabis use in medication reconciliation, and counsel patients that dispensary products have not undergone the interaction testing that FDA-approved drugs require.

This is a peer-reviewed expert commentary published as part of a special collection in Clinical Therapeutics. It presents no primary data, no systematic literature search methodology, and no formal evidence grading. In the hierarchy of evidence, it sits below systematic reviews, meta-analyses, and clinical trials, occupying the level of expert opinion. Its value lies in its practitioner-level articulation of regulatory and scientific barriers, but all interpretive claims require independent verification, particularly given the authors’ structural commercial conflict of interest.

The commentary’s central observation, that no cannabis product has navigated the FDA botanical drug pathway, is factually verifiable and consistent with the regulatory record. The four approved botanical drugs (Veregen, Mytesi, NexoBrid, Filsuvez) and five approved cannabinoid drugs (Marinol, Cesamet, Syndros, Sativex, Epidiolex) are well documented. The claim that minor cannabinoids lack preclinical characterization aligns with recent pharmacological reviews noting the absence of validated dose-response and toxicological data for compounds like CBG, CBN, and CBC. The DEA scheduling burden described here echoes concerns raised by the National Academies of Sciences, Engineering, and Medicine in their 2017 report on cannabis research barriers. Where the commentary extends beyond established literature is in its prescriptive recommendations for multi-stakeholder collaboration, a proposal that, while reasonable, lacks an evidence base of its own.

Because this is a commentary rather than a data-driven study, the most consequential analytic choice is the decision to compare the FDA botanical drug pathway favorably against state medical cannabis programs using a subjective radar plot (Figure 1B) without documented scoring methodology. Had the authors instead conducted a structured policy comparison using validated regulatory science frameworks, or included independent expert scoring, the comparison might have yielded a more balanced assessment of the tradeoffs involved. A systematic review of existing cannabis evidence against the specific regulatory requirements listed in Table 2 would have provided a far more rigorous and reproducible characterization of the evidence gaps the authors describe qualitatively. The absence of such rigor limits the document’s utility as a policy instrument.

The most likely overinterpretation is treating this commentary as evidence that the FDA botanical drug pathway is the only legitimate or appropriate route for cannabis therapeutics. The document advocates for this pathway, but Epidiolex’s approval through a standard isolate-based NDA demonstrates that the single-molecule route is fully viable and has already succeeded. Readers should also resist interpreting the radar plot figure as empirically derived comparison data; it represents the authors’ subjective assessments, not validated measurements. Finally, the document should not be cited as establishing the clinical significance of any specific evidence gap, as it presents no original data and employs selective rather than systematic citation of the literature.

This commentary provides a useful, practitioner-level map of the regulatory and scientific barriers that explain why no cannabis-derived botanical drug has ever received FDA approval. It does not generate new evidence, establish clinical efficacy for any cannabis product, or offer unbiased policy analysis, as all authors have a commercial stake in the pathway they advocate. For clinicians, its most durable contribution is a clear articulation of the evidentiary gap between dispensary-available cannabis products and FDA-approved medicines, a distinction that should inform every clinical conversation about cannabis use.

What is a botanical drug, and how is it different from a regular pharmaceutical?

A botanical drug is an FDA-recognized category for medicines derived from plants where the entire preparation, not a single isolated molecule, is considered the active ingredient. This means a whole-plant cannabis extract could potentially be approved as a botanical drug, preserving the complex mixture of cannabinoids and other plant compounds. Four non-cannabis plant-derived products have already achieved this status, but no cannabis product has yet done so.

If cannabis is available at my state dispensary, why does FDA approval matter?

State dispensary products have not undergone the same level of safety testing, dosing studies, or interaction screening that FDA-approved drugs require. This matters most if you take other prescription medications, because potential interactions between cannabinoids and common drugs have not been thoroughly studied for whole-plant preparations. FDA approval would mean a product has been rigorously evaluated for a specific medical condition at specific doses with defined safety monitoring.

Does this paper prove that any cannabis product is safe or effective?

No. This paper is a commentary that describes the challenges of developing cannabis medicines, not a clinical trial or systematic review. It does not generate any new evidence about the safety or effectiveness of any cannabis product. Its value lies in explaining why so little FDA-level evidence exists for cannabis, not in advancing that evidence itself.

Should I be concerned about drug interactions with cannabis?

Yes, this is a legitimate clinical concern. Cannabinoids, particularly CBD, can affect cytochrome P450 enzymes in the liver, which are responsible for metabolizing many common prescription medications. If you use cannabis products alongside prescription drugs, you should discuss this with your physician so potential interactions can be assessed and monitored, even though many of these interactions have not been fully characterized for dispensary products.

Have thoughts on this? Share it: